Side-by-side comparison
Compare Peptides
Pick 2–4 peptides to compare across FDA status, mechanism, research strength, half-life, side effects, and reference sources.
BPC-157
CJC-1295
Ipamorelin
Tesamorelin
| Attribute | BPC-157 Body Protection Compound-157 | CJC-1295 | Ipamorelin | Tesamorelin Egrifta |
|---|---|---|---|---|
| FDA approval status | Research / Investigational | Research / Investigational | Research / Investigational | Approved |
| Primary use | Tissue repair and GI protection (research) | Growth hormone axis stimulation (research) | GH secretagogue (research) | HIV-associated lipodystrophy (approved) |
| Mechanism of action | Modulates growth factors (VEGF, FGF), promotes angiogenesis, upregulates nitric oxide synthesis, and stabilizes cellular junctions in preclinical studies. | Binds GHRH receptors on pituitary somatotrophs to increase pulsatile growth hormone secretion. | Selective agonist of the ghrelin/GHS-R1a receptor on pituitary somatotrophs. | Stimulates pituitary GHRH receptors to increase endogenous GH secretion. |
| Research strength | Preliminary | Moderate | Moderate | Strong |
| Administration | Subcutaneous injection (research), Intramuscular (research), Oral (limited stability data) | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection, daily |
| Half-life | ~4 hours (rodent data) | ~8 days with DAC; ~30 min without DAC | ~2 hours | ~26 minutes |
| Common side effects | Injection-site irritation, Unknown long-term human effects, Possible dizziness or nausea reported anecdotally | Injection-site reactions, Flushing, Headache | Headache, Injection-site reactions, Transient flushing | Injection-site reactions, Arthralgia, Peripheral edema |
| Reconstitution | Typically reconstituted with bacteriostatic water; concentrations vary by protocol. | Bacteriostatic water; typical 2 mg vial reconstituted with 1–2 mL. | Bacteriostatic water, typically 1–2 mL per vial. | Supplied with prefilled diluent syringe per prescribing information. |
| Storage | Lyophilized: 2–8 °C long-term. Reconstituted: refrigerated, use within 30 days. | Lyophilized: freeze or refrigerate. Reconstituted: 2–8 °C, use within 2–4 weeks. | Refrigerate reconstituted vial; use within 30 days. | Refrigerate; do not freeze. |
| References |